Medtronic, Aetna Partner On Insulin Pump Cost-Savings Program
This article was originally published in The Gray Sheet
The device maker and insurance provider are collaborating to provide discounted Medtronic insulin pumps to Aetna members who have uncontrolled type 2 diabetes.
You may also be interested in...
Medtronic's outcomes-based insulin pump supply deal with Aetna is the latest example of the medtech industry's shift toward value-based care.
Novo Nordisk's oral semaglutide debuts in India at a monthly cost of about $135 and promises to transform diabetes management in the country. Will it impact the SGLT-2 inhibitor class and potentially cannibalize injectable GLP-1 receptor agonists?
US FDA hits firms in New Jersey, South Korea and China with warning letters. Meanwhile, Catalent and several outsourcing facilities work on Form 483 inspection findings as Mylan, Viona and Lohxa announce drug recalls.